Srikanth Muppidi, MD

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

17 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Muppidi’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

17 of 17 plans

Sort by

Plans whose provider directory lists this clinician

Alignment Health BreathEasy (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Clarity (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Harmony (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Honor+ Plan (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health My Choice CalCare (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Silicon (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health smartHMO (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health the ONE (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
SCAN Balance (HMO C-SNP)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN Classic (HMO)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN MyChoice (HMO)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN Strive (HMO C-SNP)	SCAN Health Plan	Listed	Oct 3, 2026
DualConnect (HMO D-SNP)	Santa Clara Family Health Plan	Listed	Sep 1, 2026

California Medical Board record

Licence C56212 · Current

Licensed to practise in California · since 2013 · expires 2027-08-31 · Ntr University of Health Sciences, Osmania Medical College.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024

See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Sort by

Every scored measure at Stanford Health Care

Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths	5.31 (4.24 to 6.37) · 8,661 cases	Worse	Jul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits	14.1 (12.7 to 15.7) · 2,191 cases	Worse	Jan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths	4.08 (1.95 to 6.21) · 5,296 cases	Better	Jul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections	0.317	Better	Oct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections	0.446	Better	Oct 2024 – Sep 2025
SSI - Colon SurgeryInfections	0.241	Better	Oct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits	0.7 (0.6 to 0.9) · 3,348 cases	Better	Jan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths	1.06 (0.45 to 1.67) · 5,374 cases	No different	Jul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths	0.86 (0.72 to 1)	No different	Jul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths	166.09 (137.88 to 194.3) · 470 cases	No different	Jul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths	1.1 · 192 cases	None	Jul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths	6.4 · 146 cases	None	Jul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths	9.7 · 253 cases	None	Jul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths	6.3 · 880 cases	None	Jul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths	10.3 · 935 cases	None	Jul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths	8.7 · 501 cases	None	Jul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths	2.1 · 7,730 cases	None	Jul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths	0.13 (0 to 0.27) · 20,799 cases	No different	Jul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths	0.28 (0.14 to 0.43) · 23,182 cases	No different	Jul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths	0.94 (0.2 to 1.68) · 5,694 cases	No different	Jul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths	2.36 (1.54 to 3.19) · 7,846 cases	No different	Jul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths	5.2 (3.76 to 6.64) · 5,603 cases	No different	Jul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths	1.38 (0.23 to 2.53) · 2,211 cases	No different	Jul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths	0.52 (0.21 to 0.83) · 19,915 cases	No different	Jul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths	3.6 · 416 cases	None	Apr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections	0.869	No different	Oct 2024 – Sep 2025
MRSA BacteremiaInfections	0.857	No different	Oct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections	0.368	No different	Oct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits	16.2 · 247 cases	None	Jul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits	20.5 · 1,021 cases	None	Jul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits	47.8 · 258 cases	None	Jul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits	-1.6 · 990 cases	None	Jul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits	20.8 · 976 cases	None	Jul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits	16.5 · 959 cases	None	Jul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits	5.2 (4.4 to 6.2) · 2,191 cases	No different	Jan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits	5.1 · 425 cases	None	Jul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits	9.6 · 158 cases	None	Jul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits	19.6 · 183 cases	None	Jul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits	12.7 (10.4 to 15.4) · 4,578 cases	No different	Jan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Sort by

Patient survey stars by topic at Stanford Health Care

Cleanliness	4
Nurse communication	4
Doctor communication	4
Communication about medicines	3
Discharge information	4
Overall hospital rating	4
Quietness	2
Recommend hospital	5

Sort by

Share of patients giving the best answer at Stanford Health Care

Room was "always" clean	75%
Nurses "always" communicated well	82%
Doctors "always" communicated well	81%
Staff "always" explained	63%
Yes, staff "did" give patients this information	89%
Yes, staff "did" give patients information about help after discharge	89%
Doctors "always" explained things so they could understand	76%
Doctors "always" listened carefully	80%
Doctors "always" treated them with courtesy and respect	87%
Patients who gave a rating of "9" or "10" (high)	79%
Staff "always" explained new medications	76%
Nurses "always" explained things so they could understand	77%
Nurses "always" listened carefully	79%
Nurses "always" treated them with courtesy and respect	88%
"Always" quiet at night	53%
"YES", patients would definitely recommend the hospital	83%
Staff "always" explained possible side effects	50%
Yes, staff "did" give patients information about possible symptoms	90%

Original Medicare doctor bills

$55,386

Medicare paid this office $55,386 for 246 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Long return visit (40+ min)	91	$14,767	$119
Long return visit (40+ min)	46	$10,062	$150
Return visit (30+ min)	41	$6,163	$116
New patient visit (60+ min)	36	$4,919	$137
Return visit (30+ min)	27	$1,950	$72

See all 14 services

Sort by

Every Original Medicare service billed

Long return visit (40+ min)	91	$14,767	$119
Long return visit (40+ min)	46	$10,062	$150
Return visit (30+ min)	41	$6,163	$116
New patient visit (60+ min)	36	$4,919	$137
Return visit (30+ min)	27	$1,950	$72
Nerve test	18	$1,629	$90
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	13	$1,444	$111
Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt	21	$1,380	$66
Nerve test	11	$1,317	$120
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or	33	$1,214	$26
Muscle electrical test	38	$895	$16
Testing of autonomic (sympathetic) nervous system function	22	$801	$35
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	47	$764	$15
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	41	$719	$15

Who their Medicare patients are

246 Original Medicare patients in 2024. Average age 70 · Under 65 17% · 85 and older 9% · Women 50% · Also on Medicaid 21% · Health risk score 1.63. Above the middle of the specialty; the typical neurology clinician is at 1.61.

Conditions among them: High blood pressure 63% · Coronary heart disease 32% · Depression 25% · Diabetes 24% · Chronic kidney disease 23% · Cancer 16% · Atrial fibrillation 15% · Heart failure 13% · COPD 13% · Stroke 11% · Dementia 9%.

The office billed $674,359, Medicare allowed $76,198 and paid $55,386; for 687 services of 27 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	246	687	70	1.63	$674,359	$55,386
2023	233	542	70	1.84	$518,673	$49,375
2022	265	630	70	1.66	$599,933	$54,227
2021	243	582	69	1.62	$581,454	$52,720
2020	245	628	69	1.70	$557,411	$40,856
2019	298	614	71	1.69	$625,319	$49,534
2018	343	809	71	1.70	$717,722	$60,857
2017	282	731	71	1.71	$750,266	$55,138
2016	277	680	71	1.58	$646,744	$52,094
2015	302	763	72	1.69	$614,414	$59,789
2014	213	552	70	1.65	$304,026	$45,965
2013	288	650	66	2.00	$190,855	$54,779

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 9 services

Sort by

Original Medicare services billed in 2023

Long return visit (40+ min)	112	$19,995	$120
Return visit (30+ min)	75	$8,628	$85
New patient visit (60+ min)	47	$7,697	$164
Initial hospital care with moderate level of medical decision making at least 75 minutes	12	$2,079	$160
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or	35	$1,479	$28
Nerve test	12	$1,169	$97
Short return visit (20+ min)	15	$915	$54
Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt	13	$846	$65
Muscle electrical test	34	$718	$16

2022: 11 services

Sort by

Original Medicare services billed in 2022

Long return visit (40+ min)	121	$21,690	$117
Return visit (30+ min)	79	$8,706	$81
New patient visit (60+ min)	46	$6,923	$151
Nerve test	22	$2,204	$100
Nerve test	16	$1,838	$115
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	11	$1,783	$94
Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt	20	$1,611	$81
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or	34	$1,435	$28
Muscle electrical test	47	$1,180	$17
Testing of autonomic (sympathetic) nervous system function	19	$796	$42
Short return visit (20+ min)	13	$718	$55

2021: 10 services

Sort by

Original Medicare services billed in 2021

Long return visit (40+ min)	123	$25,463	$124
Return visit (30+ min)	75	$8,119	$81
New patient visit (60+ min)	33	$5,638	$171
Nerve test	22	$2,680	$122
Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt	28	$2,128	$76
Nerve test	16	$1,494	$93
Muscle electrical test	47	$1,042	$17
Testing of autonomic (sympathetic) nervous system function	26	$986	$38
Short return visit (20+ min)	15	$927	$58
Muscle electrical test	14	$570	$41

2020: 12 services

Sort by

Original Medicare services billed in 2020

Return visit (30+ min)	93	$10,470	$64
Long return visit (40+ min)	55	$6,247	$92
New patient visit (60+ min)	34	$4,669	$137
Nerve test	24	$2,934	$122
Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt	35	$2,751	$79
Short return visit (20+ min)	46	$2,354	$46
Return visit (30+ min)	23	$1,772	$71
Nerve test	16	$1,568	$98
Testing of autonomic (sympathetic) nervous system function	29	$1,258	$43
Muscle electrical test	50	$1,193	$16
Muscle electrical test	16	$753	$44
Office for the evaluation and management of established patient that may not require presence of healthcare professional	11	$112	$9

2019: 11 services

Sort by

Original Medicare services billed in 2019

Long return visit (40+ min)	120	$15,900	$89
New patient visit (60+ min)	68	$9,869	$145
Return visit (30+ min)	72	$5,843	$63
Nerve test	19	$3,255	$171
Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt	40	$3,080	$77
Nerve test	19	$2,389	$119
Nerve test	13	$1,944	$150
Nerve test	20	$1,917	$96
Muscle electrical test	62	$1,309	$17
Testing of autonomic (sympathetic) nervous system function	29	$1,189	$41
Muscle electrical test	22	$962	$40

2018: 15 services

Sort by

Original Medicare services billed in 2018

Long return visit (40+ min)	118	$13,138	$88
New patient visit (60+ min)	64	$8,951	$140
Return visit (30+ min)	69	$5,789	$59
Long return visit (40+ min)	42	$4,489	$100
New patient visit (60+ min)	26	$3,913	$151
Nerve test	21	$2,437	$116
Evaluation of heart function using tilt table	30	$2,370	$79
Return visit (30+ min)	32	$2,331	$71
Nerve test	12	$2,086	$174
Nerve test	21	$1,973	$94
Muscle electrical test	56	$1,394	$16
Testing of autonomic (sympathetic) nervous system function	32	$1,275	$40
Testing of autonomic nervous system function and heart rate response to deep breathing	30	$1,199	$40
Muscle electrical test	24	$898	$37
Muscle electrical test	20	$522	$17

2017: 12 services

Sort by

Original Medicare services billed in 2017

Long return visit (40+ min)	96	$12,571	$95
New patient visit (60+ min)	73	$10,730	$147
Return visit (30+ min)	75	$7,138	$66
Nerve test	26	$4,655	$172
Evaluation of heart function using tilt table	55	$4,306	$78
Nerve test	22	$2,599	$118
Testing of autonomic nervous system function and heart rate response to deep breathing	54	$2,104	$39
Testing of autonomic (sympathetic) nervous system function	50	$2,055	$41
Muscle electrical test	64	$1,617	$17
New patient visit (45+ min)	11	$1,271	$116
Nerve test	12	$1,189	$99
Muscle electrical test	22	$939	$41

2016: 11 services

Sort by

Original Medicare services billed in 2016

Long return visit (40+ min)	77	$11,918	$97
New patient visit (60+ min)	75	$10,755	$143
Return visit (30+ min)	79	$7,042	$66
Evaluation of heart function using tilt table	56	$4,782	$85
Nerve test	29	$3,437	$119
Testing of autonomic nervous system function and heart rate response to deep breathing	53	$2,183	$41
Nerve test	20	$1,964	$98
Testing of autonomic (sympathetic) nervous system function	46	$1,890	$41
New patient visit (45+ min)	12	$1,413	$118
Muscle electrical test	30	$1,278	$43
Muscle electrical test	52	$1,190	$17

2015: 13 services

Sort by

Original Medicare services billed in 2015

Long return visit (40+ min)	104	$16,338	$92
New patient visit (60+ min)	68	$9,529	$140
Return visit (30+ min)	56	$4,925	$65
Evaluation of heart function using tilt table	52	$4,402	$85
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	17	$4,336	$92
Nerve test	34	$3,123	$92
Nerve test	18	$2,117	$118
Testing of autonomic nervous system function and heart rate response to deep breathing	51	$2,096	$41
Muscle electrical test	37	$1,622	$40
Testing of autonomic (sympathetic) nervous system function	39	$1,617	$41
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	12	$1,452	$121
Muscle electrical test	53	$1,190	$17
Nerve test	12	$804	$67

2014: 11 services

Sort by

Original Medicare services billed in 2014

New patient visit (60+ min)	92	$13,341	$145
Long return visit (40+ min)	72	$11,306	$98
Evaluation of heart function using tilt table	42	$3,422	$80
Return visit (30+ min)	38	$2,937	$70
Nerve test	23	$2,078	$90
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	13	$1,582	$122
Testing of autonomic nervous system function and heart rate response to deep breathing	34	$1,451	$41
Testing of autonomic (sympathetic) nervous system function	27	$1,122	$40
Muscle electrical test	38	$1,031	$17
Nerve test	11	$870	$73
Muscle electrical test	11	$424	$39

2013: 13 services

Sort by

Original Medicare services billed in 2013

Return visit (30+ min)	68	$8,645	$77
Long return visit (40+ min)	54	$6,975	$100
New patient visit (60+ min)	34	$4,818	$142
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	33	$4,286	$56
Nerve test	28	$3,840	$137
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	33	$3,629	$107
Testing of autonomic (sympathetic) nervous system function	18	$3,626	$201
Muscle electrical test	35	$2,093	$48
Muscle electrical test	24	$1,685	$67
Nerve test	15	$1,247	$83
Testing of autonomic nervous system function and heart rate response to deep breathing	17	$1,181	$69
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes	17	$894	$30
Muscle electrical test	17	$342	$15

Drugs they prescribed that Part D paid

$5,314,946

Pharmacies billed $5,314,946 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

878 generic and 332 brand-name prescriptions · $5,314,946 in drug cost · 24 antibiotic prescriptions.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Sort by

Largest Part D drug costs

Vyvgart	None	28	$1,295,914	$46,283
Zilbrysq	None	21	$754,804	$35,943
Gammagard Liquid	Immune globulin	67	$699,730	$10,444
Vyvgart Hytrulo	None	26	$559,073	$21,503
Gamunex-C	Immune globulin	45	$428,014	$9,511

See all 29 drugs

Sort by

Every Part D drug this clinician prescribed

Vyvgart	None	28	$1,295,914	$46,283
Zilbrysq	None	21	$754,804	$35,943
Gammagard Liquid	Immune globulin	67	$699,730	$10,444
Vyvgart Hytrulo	None	26	$559,073	$21,503
Gamunex-C	Immune globulin	45	$428,014	$9,511
Bivigam	Immune globulin	18	$337,863	$18,770
Privigen	Immune globulin	35	$250,509	$7,157
Mycophenolic Acid	None	31	$29,313	$946
Pyridostigmine Bromide Er	None	24	$13,238	$552
Rasuvo	None	23	$12,813	$557
Mycophenolate Mofetil	None	74	$11,028	$149
Pyridostigmine	None	115	$10,394	$90
Droxidopa	None	18	$6,855	$381
Azathioprine	None	56	$6,043	$108
Trexall	None	14	$4,926	$352
Midodrine	None	62	$3,728	$60
Sodium Chloride	None	48	$1,453	$30
Glycopyrrolate	None	14	$1,094	$78
Gabapentin	None	48	$756	$16
Prednisone	None	88	$724	$8
Diphenhydramine	None	45	$717	$16
Fludrocortisone Acetate	None	16	$501	$31
Duloxetine	None	20	$500	$25
Pregabalin	None	12	$477	$40
Clonazepam	None	12	$189	$16
Sulfamethoxazole-Trimethoprim	None	23	$173	$8
Clonidine	None	15	$80	$5
Pantoprazole	None	11	$77	$7
Alprazolam	None	11	$38	$3

Year by year

Sort by

Part D prescribing by year

2024	1,210	134	None	27%	$5,314,946
2023	1,107	147	None	None	$4,736,254
2022	1,012	130	None	None	$2,444,224
2021	822	100	None	None	$2,446,049
2020	763	94	None	20%	$1,172,842
2019	870	109	None	13%	$1,088,290
2018	709	113	None	None	$387,267
2017	550	105	2% (11)	14%	$287,115
2016	557	96	3% (15)	None	$103,742
2015	315	77	None	None	$96,655
2014	149	58	None	11%	$17,451
2013	416	76	None	31%	$266,018

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 25 drugs

Sort by

Part D drugs prescribed in 2023

Vyvgart	None	25	$1,362,978	$54,519
Firdapse	None	11	$595,758	$54,160
Gammagard Liquid	Immune globulin	84	$583,597	$6,948
Gamunex-C	Immune globulin	34	$281,641	$8,284
Privigen	Immune globulin	37	$268,922	$7,268
Pyridostigmine	None	128	$14,960	$117
Mycophenolic Acid	None	12	$14,808	$1,234
Pyridostigmine Bromide Er	None	16	$12,729	$796
Mycophenolate Mofetil	None	73	$12,034	$165
Droxidopa	None	20	$10,052	$503
Trexall	None	22	$9,942	$452
Rasuvo	None	11	$6,341	$576
Azathioprine	None	53	$5,644	$106
Midodrine	None	44	$4,917	$112
Sodium Chloride	None	53	$1,050	$20
Gabapentin	None	47	$1,025	$22
Fludrocortisone Acetate	None	25	$908	$36
Prednisone	None	81	$818	$10
Pregabalin	None	18	$781	$43
Methotrexate	None	13	$674	$52
Duloxetine	None	23	$605	$26
Tacrolimus	None	12	$551	$46
Diphenhydramine	None	21	$325	$15
Solu-Medrol	None	14	$259	$18
Sulfamethoxazole-Trimethoprim	None	28	$127	$5

2022: 24 drugs

Sort by

Part D drugs prescribed in 2022

Soliris	None	15	$566,902	$37,793
Privigen	Immune globulin	36	$397,751	$11,049
Flebogamma Dif	None	17	$249,088	$14,652
Gammagard Liquid	Immune globulin	32	$221,771	$6,930
Octagam	Immune globulin	26	$212,566	$8,176
Gamunex-C	Immune globulin	31	$200,217	$6,459
Pyridostigmine	None	135	$19,581	$145
Mycophenolate Mofetil	None	93	$13,519	$145
Midodrine	None	53	$10,769	$203
Diazepam	None	13	$8,194	$630
Droxidopa	None	11	$6,372	$579
Tacrolimus	None	21	$5,791	$276
Azathioprine	None	41	$4,727	$115
Gabapentin	None	70	$2,570	$37
Pregabalin	None	13	$1,090	$84
Methotrexate	None	15	$883	$59
Prednisone	None	92	$878	$10
Fludrocortisone Acetate	None	28	$838	$30
Duloxetine	None	30	$802	$27
Clonazepam	None	27	$385	$14
Carbidopa-Levodopa	None	12	$300	$25
Losartan	None	11	$153	$14
Sulfamethoxazole-Trimethoprim	None	12	$147	$12
Lorazepam	None	11	$51	$5

2021: 20 drugs

Sort by

Part D drugs prescribed in 2021

Soliris	None	36	$983,031	$27,306
Privigen	Immune globulin	46	$476,760	$10,364
Flebogamma Dif	None	18	$249,627	$13,868
Gammagard Liquid	Immune globulin	16	$168,586	$10,537
Octagam	Immune globulin	17	$143,407	$8,436
Gamunex-C	Immune globulin	26	$137,339	$5,282
Gammaplex	Immune globulin	22	$112,158	$5,098
Droxidopa	None	25	$40,164	$1,607
Pyridostigmine	None	89	$26,422	$297
Midodrine	None	70	$7,509	$107
Mycophenolate Mofetil	None	50	$6,132	$123
Azathioprine	None	42	$4,825	$115
Gabapentin	None	41	$2,643	$64
Tacrolimus	None	11	$2,240	$204
Prednisone	None	70	$750	$11
Duloxetine	None	17	$452	$27
Fludrocortisone Acetate	None	12	$398	$33
Clonazepam	None	20	$165	$8
Sulfamethoxazole-Trimethoprim	None	14	$122	$9
Sodium Chloride	None	20	$93	$5

2020: 20 drugs

Sort by

Part D drugs prescribed in 2020

Gammagard Liquid	Immune globulin	28	$226,947	$8,105
Northera	None	24	$208,351	$8,681
Gammaplex	Immune globulin	15	$182,005	$12,134
Flebogamma Dif	None	14	$179,045	$12,789
Privigen	Immune globulin	27	$154,528	$5,723
Mycophenolate Mofetil	None	45	$9,801	$218
Midodrine	None	69	$8,057	$117
Pyridostigmine	None	64	$5,124	$80
Azathioprine	None	32	$3,585	$112
Gabapentin	None	62	$1,779	$29
Duloxetine	None	28	$1,517	$54
Tacrolimus	None	12	$1,300	$108
Fludrocortisone Acetate	None	29	$1,181	$41
Prednisone	None	75	$914	$12
Captopril	None	15	$391	$26
Diclofenac	None	11	$360	$33
Carbidopa-Levodopa	None	11	$299	$27
Escitalopram	None	18	$200	$11
Solu-Medrol	None	13	$137	$11
Clonazepam	None	21	$98	$5

2019: 25 drugs

Sort by

Part D drugs prescribed in 2019

Octagam	Immune globulin	13	$274,212	$21,093
Northera	None	13	$156,088	$12,007
Gammagard Liquid	Immune globulin	20	$125,144	$6,257
Gammaked	Immune globulin	12	$120,626	$10,052
Pyridostigmine	None	101	$10,469	$104
Midodrine	None	65	$8,328	$128
Mycophenolate Mofetil	None	43	$6,406	$149
Azathioprine	None	37	$3,234	$87
Tegretol	None	11	$2,796	$254
Desmopressin Acetate	None	13	$1,641	$126
Duloxetine	None	39	$1,377	$35
Gabapentin	None	60	$1,044	$17
Fludrocortisone Acetate	None	41	$1,040	$25
Prednisone	None	74	$928	$13
Carbidopa-Levodopa	None	16	$542	$34
Nortriptyline	None	25	$369	$15
Lamotrigine	None	21	$336	$16
Levetiracetam	None	12	$282	$24
Baclofen	None	17	$228	$13
Pantoprazole	None	17	$208	$12
Sulfamethoxazole-Trimethoprim	None	20	$155	$8
Escitalopram	None	14	$132	$9
Bisoprolol	None	13	$120	$9
Potassium Chloride	None	12	$78	$6
Clonazepam	None	11	$48	$4

2018: 20 drugs

Sort by

Part D drugs prescribed in 2018

Northera	28	$158,205	$5,650
Pyridostigmine	100	$8,760	$88
Lyrica	13	$7,947	$611
Riluzole	19	$5,002	$263
Midodrine	48	$3,667	$76
Mycophenolate Mofetil	36	$2,962	$82
Tegretol	12	$2,622	$219
Gabapentin	78	$1,601	$21
Carbamazepine Er	12	$1,344	$112
Azathioprine	20	$1,292	$65
Tacrolimus	12	$1,108	$92
Duloxetine	25	$1,059	$42
Prednisone	71	$934	$13
Fludrocortisone Acetate	18	$650	$36
Oxcarbazepine	17	$526	$31
Carbidopa-Levodopa	15	$466	$31
Nortriptyline	18	$249	$14
Escitalopram	14	$127	$9
Sulfamethoxazole-Trimethoprim	12	$116	$10
Clonazepam	14	$47	$3

2017: 16 drugs

Sort by

Part D drugs prescribed in 2017

Northera	34	$249,743	$7,345
Pyridostigmine	78	$6,866	$88
Midodrine	42	$3,978	$95
Tegretol	12	$2,466	$206
Riluzole	13	$2,015	$155
Mycophenolate Mofetil	11	$1,470	$134
Oxcarbazepine	24	$927	$39
Carbidopa-Levodopa	34	$885	$26
Donepezil	11	$837	$76
Gabapentin	64	$833	$13
Duloxetine	20	$820	$41
Fludrocortisone Acetate	19	$730	$38
Prednisone	50	$709	$14
Tramadol	11	$87	$8
Metoprolol	11	$80	$7
Clonazepam	12	$71	$6

2016: 16 drugs

Sort by

Part D drugs prescribed in 2016

Northera	17	$71,557	$4,209
Pyridostigmine	67	$5,226	$78
Albuterol Sulfate	11	$4,621	$420
Modafinil	11	$3,328	$303
Tegretol	12	$2,201	$183
Midodrine	40	$1,784	$45
Oxcarbazepine	32	$1,321	$41
Carbidopa-Levodopa	30	$1,105	$37
Gabapentin	74	$857	$12
Duloxetine	13	$699	$54
Fludrocortisone Acetate	21	$565	$27
Prednisone	41	$523	$13
Mycophenolate Mofetil	13	$490	$38
Nortriptyline	19	$327	$17
Levetiracetam	19	$315	$17
Tramadol	12	$72	$6

2015: 12 drugs

Sort by

Part D drugs prescribed in 2015

Northera	17	$75,180	$4,422
Lyrica	21	$6,651	$317
Duloxetine	16	$1,770	$111
Pyridostigmine	14	$987	$70
Carbidopa-Levodopa	18	$723	$40
Fludrocortisone Acetate	15	$515	$34
Oxcarbazepine	16	$485	$30
Nortriptyline	18	$413	$23
Prednisone	23	$357	$16
Gabapentin	33	$336	$10
Potassium Chloride	11	$125	$11
Topiramate	11	$66	$6

2014: 2 drugs

Sort by

Part D drugs prescribed in 2014

Duloxetine	22	$5,412	$246
Nortriptyline	14	$163	$12

2013: 8 drugs

Sort by

Part D drugs prescribed in 2013

Gammagard Liquid	Immune globulin	17	$206,043	$12,120
Cymbalta	None	42	$18,052	$430
Mycophenolate Mofetil	None	48	$6,341	$132
Gabapentin	None	70	$3,280	$47
Nexium	None	11	$3,195	$290
Pyridostigmine	None	28	$1,423	$51
Nortriptyline	None	16	$242	$15
Prednisone	None	26	$241	$9

Money from drug and device companies

$31,636 in 2025

Sort by

Industry payments by year

2025	4	21	$19,925	$31,636
2024	12	39	$45,472	$48,695
2023	5	17	$10,095	$10,642
2022	5	33	$38,629	$40,142
2021	1	2	$5,088	$5,088
2020	4	5	$4,655	$4,681
2019	2	19	$5,960	$8,864

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

Ucb Sa	None	$16,626	3 payments Consulting · 2025-12-05 · $5,440 Travel · 2025-10-16 · $1,017 Travel · 2025-10-16 · $10,169
Alexion Pharmaceuticals	Ultomiris	$8,648	9 payments Travel for Ultomiris · 2025-10-27 · $36 Meals for Ultomiris · 2025-10-27 · $45 Consulting for Ultomiris · 2025-10-27 · $5,310 Meals for Ultomiris · 2025-10-27 · $23 Meals for Ultomiris · 2025-10-27 · $23 Meals for Ultomiris · 2025-10-27 · $40 Meals for Ultomiris · 2025-10-27 · $46 Consulting for Ultomiris · 2025-08-12 · $2,950 Consulting for Ultomiris · 2025-03-27 · $175
Amgen	Uplizna	$6,050	4 payments Consulting for Uplizna · 2025-12-04 · $1,650 Consulting for Uplizna · 2025-09-30 · $2,200 Consulting for Uplizna · 2025-06-18 · $1,650 Consulting for Uplizna · 2025-05-12 · $550
Argenx US	None	$312	5 payments Meals · 2025-04-24 · $75 Meals · 2025-04-24 · $31 Meals · 2025-04-24 · $50 Meals · 2025-04-24 · $31 Meals · 2025-04-23 · $125

See all 21 published payments

Sort by

Every published payment

Ucb Sa	Consulting · 2025-12-05	None	$5,440
Amgen	Consulting · 2025-12-04	Uplizna	$1,650
Alexion Pharmaceuticals	Travel · 2025-10-27	Ultomiris	$36
Alexion Pharmaceuticals	Meals · 2025-10-27	Ultomiris	$45
Alexion Pharmaceuticals	Consulting · 2025-10-27	Ultomiris	$5,310
Alexion Pharmaceuticals	Meals · 2025-10-27	Ultomiris	$23
Alexion Pharmaceuticals	Meals · 2025-10-27	Ultomiris	$23
Alexion Pharmaceuticals	Meals · 2025-10-27	Ultomiris	$40
Alexion Pharmaceuticals	Meals · 2025-10-27	Ultomiris	$46
Ucb Sa	Travel · 2025-10-16	None	$1,017
Ucb Sa	Travel · 2025-10-16	None	$10,169
Amgen	Consulting · 2025-09-30	Uplizna	$2,200
Alexion Pharmaceuticals	Consulting · 2025-08-12	Ultomiris	$2,950
Amgen	Consulting · 2025-06-18	Uplizna	$1,650
Amgen	Consulting · 2025-05-12	Uplizna	$550
Argenx US	Meals · 2025-04-24	None	$75
Argenx US	Meals · 2025-04-24	None	$31
Argenx US	Meals · 2025-04-24	None	$50
Argenx US	Meals · 2025-04-24	None	$31
Argenx US	Meals · 2025-04-23	None	$125
Alexion Pharmaceuticals	Consulting · 2025-03-27	Ultomiris	$175

See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $48,695

Sort by

Payments by company in 2024

Amgen	Uplizna	$13,070	12 payments Meals for Uplizna · 2024-10-18 · $21 Travel for Uplizna · 2024-10-18 · $239 Meals for Uplizna · 2024-10-18 · $50 Consulting for Uplizna · 2024-10-18 · $4,950 Travel for Uplizna · 2024-05-18 · $175 Meals for Uplizna · 2024-05-18 · $22 Meals for Uplizna · 2024-05-18 · $23 Meals for Uplizna · 2024-05-18 · $42 Meals for Uplizna · 2024-05-18 · $52 Travel for Uplizna · 2024-05-18 · $727 Consulting for Uplizna · 2024-05-18 · $6,600 Travel for Uplizna · 2024-05-17 · $168
Alexion Pharmaceuticals	Ultomiris	$11,491	4 payments Consulting for Ultomiris · 2024-10-30 · $4,720 Travel for Ultomiris · 2024-10-13 · $281 Consulting for Ultomiris · 2024-09-23 · $5,310 Consulting for Soliris · 2024-05-14 · $1,180
Takeda Pharmaceuticals U.S.A.	None	$9,464	10 payments Consulting · 2024-10-03 · $8,357 Travel · 2024-10-03 · $53 Travel · 2024-10-03 · $56 Travel · 2024-07-27 · $238 Travel · 2024-07-27 · $608 Meals · 2024-07-27 · $30 Meals · 2024-07-27 · $22 Meals · 2024-07-27 · $50 Meals · 2024-07-27 · $35 Meals · 2024-07-27 · $15
Janssen Biotech	None	$3,815	1 payment Consulting · 2024-08-19 · $3,815
Merck KGaA	None	$2,813	2 payments Consulting · 2024-12-23 · $2,790 Meals · 2024-10-26 · $23
Argenx US	Vyvgart	$2,303	2 payments Meals for Vyvgart · 2024-10-16 · $3 Consulting for Vyvgart · 2024-03-14 · $2,300
Ucb Sa	None	$1,650	1 payment Consulting · 2024-01-12 · $1,650
Ucb	Rystiggo	$1,620	3 payments Meals · 2024-12-13 · $4 Meals · 2024-10-17 · $16 Consulting for Rystiggo · 2024-08-27 · $1,600
Janssen Global Services	None	$1,110	1 payment Consulting · 2024-12-05 · $1,110
Janssen Scientific Affairs	None	$1,090	1 payment Consulting · 2024-10-11 · $1,090
Alnylam Pharmaceuticals	None	$138	1 payment Meals · 2024-03-21 · $138
Novartis Pharmaceuticals	None	$131	1 payment Meals · 2024-04-14 · $131

2023: $10,642

Sort by

Payments by company in 2023

Argenx US	Vyvgart	$5,561	11 payments Consulting for Vyvgart · 2023-11-21 · $2,588 Meals for Vyvgart · 2023-10-31 · $16 Meals for Vyvgart · 2023-10-31 · $24 Meals for Vyvgart · 2023-10-31 · $62 Meals for Vyvgart · 2023-10-31 · $117 Meals for Vyvgart · 2023-10-31 · $54 Meals for Vyvgart · 2023-10-31 · $4 Consulting for Vyvgart · 2023-09-05 · $863 Consulting for Vyvgart · 2023-07-11 · $575 Meals for Vyvgart · 2023-04-23 · $111 Consulting for Vyvgart · 2023-04-20 · $1,150
Amgen	None	$3,000	2 payments Consulting · 2023-11-01 · $600 Consulting · 2023-11-01 · $2,400
Alexion Pharmaceuticals	Soliris	$1,770	1 payment Consulting for Soliris · 2023-05-10 · $1,770
Ucb	None	$161	2 payments Meals · 2023-11-03 · $11 Meals · 2023-11-02 · $151
Sobi	Tegsedi	$150	1 payment Consulting for Tegsedi · 2023-09-20 · $150

2022: $40,142

Sort by

Payments by company in 2022

Alexion Pharmaceuticals	Soliris	$13,196	19 payments Consulting · 2022-10-12 · $2,040 Consulting for Soliris · 2022-10-12 · $2,295 Meals for Soliris · 2022-09-24 · $53 Meals for Soliris · 2022-09-24 · $26 Meals for Soliris · 2022-09-24 · $26 Travel for Soliris · 2022-09-24 · $197 Meals for Soliris · 2022-09-24 · $38 Meals for Ultomiris · 2022-09-21 · $97 Consulting for Soliris · 2022-08-17 · $1,530 Consulting for Soliris · 2022-07-07 · $4,590 Travel for Soliris · 2022-05-25 · $225 Meals for Soliris · 2022-05-13 · $22 Travel for Soliris · 2022-05-13 · $26 Meals for Soliris · 2022-05-13 · $22 Meals for Soliris · 2022-05-13 · $22 Meals for Soliris · 2022-05-13 · $50 Meals for Soliris · 2022-05-13 · $30 Meals for Soliris · 2022-05-12 · $121 Consulting for Soliris · 2022-04-13 · $1,785
Argenx US	Vyvgart	$10,203	9 payments Consulting for Vyvgart · 2022-10-26 · $5,175 Meals for Vyvgart · 2022-09-20 · $71 Meals for Vyvgart · 2022-09-20 · $46 Meals for Vyvgart · 2022-09-20 · $73 Consulting for Vyvgart · 2022-08-31 · $3,450 Meals for Vyvgart · 2022-08-31 · $79 Travel · 2022-07-05 · $94 Meals · 2022-07-05 · $66 Consulting · 2022-06-29 · $1,150
Ucb Sa	None	$9,213	2 payments Consulting · 2022-05-20 · $5,913 Consulting · 2022-01-07 · $3,300
Ucb	Zilbrysq	$5,731	2 payments Consulting for Zilbrysq · 2022-11-15 · $5,602 Meals · 2022-09-22 · $129
Horizon Therapeutics plc	Uplizna	$1,800	1 payment Honoraria for Uplizna · 2022-05-18 · $1,800

2021: $5,088

Sort by

Payments by company in 2021

Ucb	None	$5,088	2 payments Consulting · 2021-12-13 · $2,063 Consulting · 2021-01-21 · $3,025

2020: $4,681

Sort by

Payments by company in 2020

Catalyst Pharmaceuticals	Firdapse	$2,500	2 payments Consulting for Firdapse · 2020-10-19 · $1,250 Consulting for Firdapse · 2020-10-01 · $1,250
CSL Behring	Hizentra	$1,645	1 payment Honoraria for Hizentra · 2020-11-21 · $1,645
Alexion Pharmaceuticals	None	$510	1 payment Honoraria · 2020-12-18 · $510
Biogen	Spinraza	$26	1 payment Meals for Spinraza · 2020-02-29 · $26

2019: $8,864

Sort by

Payments by company in 2019

Alexion Pharmaceuticals	Soliris	$8,840	18 payments Travel · 2019-11-16 · $125 Meals · 2019-10-26 · $238 Meals · 2019-10-25 · $284 Travel · 2019-10-24 · $308 Travel · 2019-10-24 · $288 Paid to speak or teach for Soliris · 2019-06-12 · $3,960 Travel for Soliris · 2019-06-09 · $40 Meals for Soliris · 2019-06-08 · $10 Meals for Soliris · 2019-06-08 · $12 Travel for Soliris · 2019-06-08 · $257 Meals for Soliris · 2019-06-08 · $34 Travel for Soliris · 2019-06-08 · $44 Meals for Soliris · 2019-06-08 · $46 Travel for Soliris · 2019-06-08 · $68 Travel for Soliris · 2019-06-07 · $37 Travel for Soliris · 2019-06-07 · $997 Consulting · 2019-05-25 · $2,000 Meals · 2019-05-05 · $92
Catalyst Pharmaceuticals	Firdapse	$25	1 payment Meals for Firdapse · 2019-10-17 · $25

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Sort by

Research payments by company and study

ARGENX US, INC. · A Long-Term, Single-Arm, Open-Label, Multicenter Phase 3 Study To Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod Ph20 Sc in Patients With Generalized Myasthenia Gravis · 2022	Their institution	$129,186
ARGENX US, INC. · A Long-Term, Single Arm, Open-Label, Multicenter, Phase 3 Study To Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod Ph20 Sc in Patients With Generalized Myasthenia Gravis. · 2025	Their institution	$117,669
Alexion Pharmaceuticals, Inc. · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Nave Adult Patients With Generalized Myasthenia Gravis · 2021	Their institution	$72,109
ARGENX US, INC. · A Long-Term, Single-Arm, Open-Label, Multicenter Phase 3 Study To Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod Ph20 Sc in Patients With Generalized Myasthenia Gravis · 2023	Their institution	$67,015
Alexion Pharmaceuticals, Inc. · Randomized, Double Blind, Placebo Controlled, Multicenter Study To Evaluate the Safety and Efficacy of Ravulizumab in Complement Inhibitor Naive Adult Patients With Generalized Myasthenia Gravis · 2023	Their institution	$59,948
Alexion Pharmaceuticals, Inc. · Randomized, Double Blind, Placebo Controlled, Multicenter Study To Evaluate the Safety and Efficacy of Ravulizumab in Complement Inhibitor Naive Adult Patients With Generalized Myasthenia Gravis · 2022	Their institution	$43,849
Alexion Pharmaceuticals, Inc. · Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis · 2020	Their institution	$36,748
Alexion Pharmaceuticals, Inc. · A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study To Evaluate the Efficacy and Safety of Alxn2050 in Adult Participants With Generalized Myasthe · 2022	Their institution	$29,464
Alexion Pharmaceuticals, Inc. · A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study To Evaluate the Efficacy and Safety of Alxn2050 in Adult Participants With Generalized Myasthe · 2023	Their institution	$17,498
Alexion Pharmaceuticals, Inc. · Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis · 2019	This clinician	$17,446
ARGENX US, INC. · A Long-Term, Single Arm, Open-Label, Multicenter, Phase 3 Study To Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod Ph20 Sc in Patients With Generalized Myasthenia Gravis. · 2024	Their institution	$15,654
Alexion Pharmaceuticals, Inc. · An Extension Trial of Ecu-Mg-301 To Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis · 2019	Their institution	$13,329
ARGENX US, INC. · A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of Argx-113-1704 To Evaluate the Safety and Tolerability of Argx-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness · 2023	Their institution	$9,240
Novartis Pharma AG · Lnp023q12301 and Lou064o12301. · 2025	This clinician	$989
Novartis Pharma AG · Lnp023q12301 & Lou064o12301 · 2025	This clinician	$12

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score: 76.5 / 100; Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI: 1568641736
Licence: CA C56212California C56212: Current · expires 2027-08-31
Group: Stanford Health Care
Video visits: Lists video visits
Gender: Male

More record details

Sole proprietor: No
Taxonomy: Federal specialty code 2084N0600X (2084N0600X); Federal specialty code 2084N0008X (2084N0008X); Neurology (2084N0400X)
Mailing address: 300 Pasteur Dr, Stanford, CA, 94305
NPI first listed: 2007-10-24
NPI last updated: 2023-11-10
NPI record certified: 2023-11-10

This is when the NPI record was last certified, not a medical board exam.